Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

@inproceedings{Li2018Phosphodiesterase4IF,
  title={Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases},
  author={Heng Li and Jianping Zuo and Wei Tang},
  booktitle={Front. Pharmacol.},
  year={2018}
}
Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and epithelial integrity. Inhibition of PDE4 is predicted to have diverse effects via the elevation of the level of cyclic adenosine monophosphate (cAMP) and the subsequent regulation of a wide array of genes and proteins. It has been identified that PDE4 is a promising therapeutic target for the treatment of diverse… CONTINUE READING
2
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Inhibition of PDE4 Attenuates TNF-α-Triggered Cell Death Through Suppressing NF-κB and JNK Activation in HT-22 Neuronal Cells

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 174 REFERENCES

2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.

VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

The psoriasis drugs market

VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Phosphodiesterase 4 inhibitors

VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.

VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Apremilast

  • D. J. Cada, K. Ingram, D. E. Baker
  • Hosp. Pharm. 49, 752–762. doi: 10.1310/hpj4908-752
  • 2014
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL